We are live on
!
Find out more
Arrowstreet Capital Portfolio holdings
AUM
$185B
1-Year Est. Return
39.58%
This Fund
S&P 500
This Quarter
Est. Return
+2.04%
1 Year Est. Return
+39.58%
3 Year Est. Return
+145.48%
5 Year Est. Return
+192.07%
10 Year Est. Return
+749.68%
AUM
$16.2B
AUM Growth
-$1.27B
(-7.2%)
Cap. Flow
-$1.42B
Cap. Flow
% of AUM
-8.75%
Top 10 Holdings %
Top 10 Hldgs %
18.5%
Holding
1,414
New
206
Increased
348
Reduced
372
Closed
450
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$456M |
| 2 |
Intel
INTC
|
+$290M |
| 3 |
Union Pacific
UNP
|
+$159M |
| 4 |
AT&T
T
|
+$143M |
| 5 |
Philip Morris
PM
|
+$130M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceuticals
TEVA
|
+$394M |
| 2 |
AstraZeneca
AZN
|
+$307M |
| 3 |
Gilead Sciences
GILD
|
+$212M |
| 4 |
TSMC
TSM
|
+$187M |
| 5 |
Canadian National Railway
CNI
|
+$177M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 28.82% |
| 2 | Financials | 15.5% |
| 3 | Healthcare | 9.75% |
| 4 | Industrials | 8.83% |
| 5 | Consumer Discretionary | 8.82% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
576
Brown & Brown
BRO
$23.9B
| $2.31M | 0.01% |
139,866
+56,726
| +68% | +$916K |
|
|
SCS
577
DELISTED
Steelcase
SCS
| $2.31M | 0.01% |
122,121
+67,669
| +124% | +$1.22M |
|
578
Factset
FDS
$10.2B
| $2.31M | 0.01% |
+14,500
| New | +$2.17M |
|
579
Cognex
CGNX
$11.3B
| $2.29M | 0.01% |
+92,356
| New | +$1.96M |
|
580
Innospec
IOSP
$2.28B
| $2.28M | 0.01% |
+49,229
| New | +$2.11M |
|
581
KT
KT
$8.81B
| $2.27M | 0.01% |
173,703
-395,163
| -69% | -$5.36M |
|
582
Citi Trends
CTRN
$605M
| $2.26M | 0.01% |
83,741
| – | – |
|
583
Sonoco
SON
$5.74B
| $2.23M | 0.01% |
49,171
-33,252
| -40% | -$1.51M |
|
|
FGL
584
DELISTED
Fidelity & Guaranty Life
FGL
| $2.23M | 0.01% |
105,437
-7,370
| -7% | -$161K |
|
585
Alkermes
ALKS
$8.25B
| $2.21M | 0.01% |
+36,200
| New | +$2.47M |
|
|
BBRG
586
DELISTED
Bravo Brio Restaurant Group Inc.
BBRG
| $2.2M | 0.01% |
149,773
-2,600
| -2% | -$35.7K |
|
|
AXLL
587
DELISTED
AXIALL CORP COM STK (DE)
AXLL
| $2.16M | 0.01% |
45,958
-93,755
| -67% | -$4.23M |
|
|
RP
588
DELISTED
RealPage, Inc.
RP
| $2.13M | 0.01% |
+106,018
| New | +$2.1M |
|
|
EXL
589
DELISTED
EXCEL TRUST , INC COM STK
EXL
| $2.13M | 0.01% |
151,692
+444
| +0.3% | +$6.17K |
|
590
Biglari Holdings Class B
BH
$1.21B
| $2.11M | 0.01% |
7,635
| – | – |
|
|
CPHD
591
DELISTED
Cepheid Inc
CPHD
| $2.09M | 0.01% |
+36,700
| New | +$2.06M |
|
592
Rush Enterprises Class A
RUSHA
$6.22B
| $2.06M | 0.01% |
169,484
-200,567
| -54% | -$2.54M |
|
|
IBA
593
DELISTED
Industrias Bachoco SAB De C.V.
IBA
| $2.05M | 0.01% |
41,156
+13,212
| +47% | +$666K |
|
|
SCAI
594
DELISTED
Surgical Care Affiliates, Inc.
SCAI
| $2.03M | 0.01% |
59,231
+50,700
| +594% | +$1.69M |
|
595
Aaon
AAON
$7.77B
| $2.03M | 0.01% |
124,214
-9,054
| -7% | -$137K |
|
|
BEE
596
DELISTED
STRATEGIC HOTELS & RESORTS, INC
BEE
| $2.03M | 0.01% |
163,011
-129,213
| -44% | -$1.69M |
|
597
Silgan Holdings
SLGN
$4.41B
| $2.01M | 0.01% |
69,120
+60,068
| +664% | +$1.67M |
|
598
Williams-Sonoma
WSM
$29.6B
| $1.99M | 0.01% |
+49,800
| New | +$1.97M |
|
599
NatWest
NWG
$76.4B
| $1.97M | 0.01% |
181,220
+144,796
| +398% | +$1.75M |
|
600
Perdoceo Education
PRDO
$2.12B
| $1.96M | 0.01% |
389,073
+334,150
| +608% | +$1.93M |
|
Similar funds
VGA
Arrowstreet Capital's Q1 2015 Portfolio in Review
As of Q1 2015, Arrowstreet Capital held 1,414 positions worth $16.2B, down 7.2% from $17.5B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Arrowstreet Capital withdrew a net $1.42B in Q1 2015, closing 450 positions and reducing 372 holdings. Its most notable exit was Teva Pharmaceuticals, an estimated $394M position sold in full.
By sector, the portfolio is most concentrated in Technology at 29% of assets, up from 21% a quarter earlier, followed by Financials and Healthcare.
Against the trend, Arrowstreet Capital opened a new position in Apple worth $470M.
- Arrowstreet Capital's largest Q1 2015 buy was Apple: 15,110,160 shares worth $470M.
- Arrowstreet Capital added most to Intel in Q1 2015, an estimated $290M increase.
- Arrowstreet Capital's biggest Q1 2015 reduction was AstraZeneca, cutting an estimated $307M.
- Arrowstreet Capital fully exited Teva Pharmaceuticals in Q1 2015, selling an estimated $394M.
- Arrowstreet Capital's ten largest holdings make up 18% of its $16.2B portfolio in Q1 2015.
- Arrowstreet Capital opened 206 new positions and closed 450 in Q1 2015.
- Arrowstreet Capital's portfolio value fell 7.2% quarter-over-quarter to $16.2B.
Based on Arrowstreet Capital's 13F filing for Q1 2015, filed 15 May 2015.